{"id":531041,"date":"2021-02-20T18:28:01","date_gmt":"2021-02-20T18:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531041"},"modified":"2021-02-20T18:28:01","modified_gmt":"2021-02-20T18:28:01","slug":"infliximab-biosimilar-landscape-report-2020-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/infliximab-biosimilar-landscape-report-2020-by-delveinsight_531041.html","title":{"rendered":"Infliximab Biosimilar Landscape Report 2020 by DelveInsight"},"content":{"rendered":"
\"Infliximab<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cInfliximab\u2013 Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in the Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/div>\n

DelveInsight launched a new report on Infliximab Biosimilar Insights 2020<\/strong><\/a>.<\/p>\n

DelveInsight’s, “Infliximab Biosimilar Insight, 2020<\/strong><\/a>,” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in the Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. <\/p>\n

\"\"<\/p>\n

Infliximab Overview:<\/strong><\/p>\n

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease.<\/p>\n

Request for a detailed sample copy of the report: https:\/\/www.delveinsight.com\/sample-request\/infliximab-biosimilars-insight<\/a><\/strong><\/p>\n

Infliximab Marketed Drugs:<\/strong><\/p>\n

1. Inflectra: Celltrion\/Pfizer<\/p>\n

2. Renflexis: Merck<\/p>\n

Infliximab Emerging Drugs:<\/strong><\/p>\n

1. BCD 055: Biocad<\/p>\n

2. CT-P17: Celltrion<\/p>\n

Pipeline Development Activities<\/strong><\/p>\n

The report covers detailed information on collaborations, acquisition, and merger, licensing along a thorough therapeutic assessment of emerging Infliximab biosimilar drugs.<\/p>\n

Click here and get access to free sample pages of the report.<\/strong><\/a><\/p>\n

Table of contents:<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Infliximab Biosimilars: Snapshot<\/p>\n

3. Executive Summary<\/p>\n

4. Regulatory Outlook For Biosimilars<\/p>\n

5. Infliximab (Reference Product: Remicade)<\/p>\n

6. Research and Development<\/p>\n

7. Remicade Biosimilar: Emerging Opportunities<\/p>\n

8. Infliximab: Biosimilars Assessment<\/p>\n

9. Infliximab Biosimilars Profiles: By Company<\/p>\n

10. Infliximab Biosimilars: Comparative Landscape: By Company<\/p>\n

11. Infliximab Biosimilars: Competitive Landscape<\/p>\n

12. Market Drivers<\/p>\n

13. Market Barriers<\/p>\n

14. SWOT Analysis<\/p>\n

15. Appendix <\/p>\n

16. Bibliography<\/p>\n

17. DelveInsight Capabilities<\/p>\n

18. Disclaimer<\/p>\n

19. About DelveInsight<\/p>\n

Download free report: https:\/\/www.delveinsight.com\/report-store\/infliximab-biosimilars-insight<\/span><\/a><\/strong><\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s, \u201cInfliximab\u2013 Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in the Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531041","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531041"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531041\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}